Your browser doesn't support javascript.
loading
Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
Abelleira, Erika; Peñaloza, Mirna Angela; Jerkovich, Fernando; Bueno, Fernanda; Pitoia, Fabián.
  • Abelleira, Erika; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Peñaloza, Mirna Angela; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Jerkovich, Fernando; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Bueno, Fernanda; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Pitoia, Fabián; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
Arch. endocrinol. metab. (Online) ; 65(3): 315-321, May-June 2021. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1285151
ABSTRACT
ABSTRACT

Objective:

The treatment of patients with differentiated thyroid cancer (DTC) was modified in the last decade towards a more individualized approach according to the risk of recurrence (RR). We compared the outcomes of patients with low and intermediate RR (LRR and IRR) who received or did not receive radioiodine remnant ablation (RRA) after assessing the dynamic risk. Materials and

methods:

We included 307 DTC patients with LRR and IRR submitted to total thyroidectomy. All patients were reclassified according to the dynamic risk stratification (low or high). Patients with high dynamic risk received RRA (141 patients).

Results:

LRR patients who received RRA presented a frequency of structural incomplete response (SIR) of 5% at the end of the follow-up, compared to 2% in those who did not receive it (p=0.353). IRR patients treated with RRA had a frequency of SIR of 22%, compared to 5% in patients without RRA (p=0.008).

Conclusions:

This study demonstrates the usefulness of dynamic risk assessment to decide RRA in a cohort with a long-term follow-up. The lower prevalence of SIR at the end of the follow-up in patients who did not receive RRA highlights the adequate selection of those who would not benefit from RRA, even with an intermediate risk of recurrence.
Asunto(s)


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Neoplasias de la Tiroides / Radioisótopos de Yodo Tipo de estudio: Estudio de etiología / Estudio observacional / Factores de riesgo Límite: Humanos Idioma: Inglés Revista: Arch. endocrinol. metab. (Online) Asunto de la revista: Endocrinologia / Metabolismo Año: 2021 Tipo del documento: Artículo País de afiliación: Argentina Institución/País de afiliación: University of Buenos Aires/AR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Neoplasias de la Tiroides / Radioisótopos de Yodo Tipo de estudio: Estudio de etiología / Estudio observacional / Factores de riesgo Límite: Humanos Idioma: Inglés Revista: Arch. endocrinol. metab. (Online) Asunto de la revista: Endocrinologia / Metabolismo Año: 2021 Tipo del documento: Artículo País de afiliación: Argentina Institución/País de afiliación: University of Buenos Aires/AR